NeoMedix Corporation to Present at Medtech Insight's ``Investment in Innovation'' Conference.Business Editors/Health/Medical Writers Medtech Insight 2004 Investment in Innovation IRVINE, Calif.--(BUSINESS WIRE)--Feb. 20, 2004 NeoMedix Corporation announced today that it will present at the Medtech Insight Conference on February 23rd, 2004 at 3:20 pm. The conference features biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. device companies and is being held at the Hyatt Regency in Irvine, CA. NeoMedix recently announced FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance of its new Trabectome(TM) technology for the treatment of Glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). . Glaucoma is the second leading cause of blindness afflicting af·flict tr.v. af·flict·ed, af·flict·ing, af·flicts To inflict grievous physical or mental suffering on. [Middle English afflighten, from afflight, 11 million patients globally, consisting of 2% of US population. Trabectome(TM) technology is designed for easy, cost effective, with no or low postoperative post·op·er·a·tive adj. Happening or done after a surgical operation. postoperative after a surgical operation. postoperative care maintenance of glaucoma treatment. Trabectome(TM), a patented (US and foreign patents pending) device, is designed to overcome the deficiencies of conventional technologies: -- Trabectome(TM) utilizes less-invasive ab-interno operating principles via 1.5 mm corneal corneal pertaining to the cornea. See also keratitis, keratopathy. corneal anomaly includes microcornea, coloboma, megalocornea, dermoid, congenital opacity. corneal black body see corneal sequestrum (below). incision incision /in·ci·sion/ (in-sizh´un) 1. a cut or a wound made by cutting with a sharp instrument.incis´ional 2. the act of cutting. in·ci·sion n. 1. reducing operative and postoperative trauma significantly. -- Trabectome(TM) is performed under local anesthesia Anesthesia, Local Definition Local or regional anesthesia involves the injection or application of an anesthetic drug to a specific area of the body, as opposed to the entire body and brain as occurs during general anesthesia. in an outpatient basis due to its less-traumatic, minimally invasive nature. -- Trabectome(TM) cost is $5-$10K console and $300 per disposable and maintaining reasonable reimbursement rates for the physician and the surgi-center. Therefore, resulting in improved operative performance at reduced costs. -- Trabectome(TM) procedure leaves the basic physiology of the eye intact increasing patient comfort, vision prospects, and avoids potential post-operative complications which are common to most Glaucoma procedures. Trabectome(TM) has been market field evaluated on 19 patients with over 9 months follow-up with very encouraging results. 30 additional marketing field evaluations are initiated by leading glaucoma US and foreign surgeons. NeoMedix Corporation, based in San Juan Capistrano, California San Juan Capistrano is a city in southern Orange County, California, USA, located approximately 23 miles southeast of Downtown Santa Ana. The current OMB metropolitan designation for San Juan Capistrano and the Orange County Area is “Santa Ana-Anaheim-Irvine, CA. , is engaged in designing, developing, and global marketing of new ophthalmic medical Device technologies and related products that are easy to use, cost effective and provide higher patient comfort. For more information about NeoMedix Corporation, please see www.NeoMedix.net. NeoMedix Corporation has secured $4.5M investments from its founders on Trabectome(TM) and is currently seeking ($2-$2.5M) capital for Market launch of the Trabectome(TM) technology at the American Glaucoma Society The American Glaucoma Society is a subspecialty society in ophthalmology that promotes education and research about glaucoma among physicians and scientists. Founded in 1985 by thirteen original members, it now has more than 400 members. See also Charles D. annual meeting in spring of 2005. About Medtech Insight Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" conferences are considered the premier forum for senior executives in the medical technology and investment community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. In addition to conferences, Medtech Insight publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the Irvine conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail in3@medtechinsight.com, or visit http://www.medtechinsight.com/in3-10.html. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion